“Biopharmaceutical Third Party Logistics (3PL) Market Worth $87.62 Billion in 2019”, says Visiongain report

19 December 2019
Pharma

Visiongain’s new report the Biopharmaceutical Third Party Logistics (3PL) Market Report 2019-2029: Forecasts by Supply Chain (Cold Chain, Non-Cold Chain), by Service Service Type (Transportation {Air Freight , Sea Freight , Overland Transportation}, Warehousing and Storage, Others), plus analysis of leading companies indicates that the global Biopharmaceutical Third Party Logistics (3PL) market will attain $137 billion revenue by 2029.

Global Biopharmaceutical Third Party Logistics market is expected to grow on account of increasing sales of biopharmaceutical and growing demand for safe delivery services for temperature-sensitive biologics. The market is expected to grow at a healthy CAGR of 4.6% over the projected period. In addition, increased demand for safe storage and transport of temperature-sensitive biopharmaceutical products are anticipated to reinforce the market concentration of biopharmaceutical 3PL over the projected period.

Over the past few years, demand for transportation outsourcing services has risen considerably. Outsourcing transportation services have led to reduced significant overheads of giant pharmaceutical companies. In addition, large biopharmaceutical businesses either sign an agreement or outsource services to 3PL service suppliers to decrease general operating costs, resulting in reduced pharmaceutical product prices. This has elevated the demand for biopharmaceutical 3PL services among giant biopharmaceutical companies.

In 2019, the Asia Pacific Biopharmaceutical Third Party Logistics (3PL) market accounted for more than 30% of overall market share. Strong economic growth followed by increasing sales of biopharmaceutical products in India, Japan, China, and Singapore is expected to increase Biopharmaceutical Third Party Logistics (3PL) market penetration over the forecast period. Asia Pacific market is growing on account of the growing aging population, the rising number of diseases is demanding for biologics and pharmaceuticals and high presence of CRO’s in the region.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever